Longitudinal study of neuropathic pain in patients with Guillain-Barré syndrome.
Guillain-Barré syndrome
Neuropathic pain
Non-neuropathic pain
Therapy
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
09
07
2020
accepted:
07
10
2020
pubmed:
16
10
2020
medline:
5
10
2021
entrez:
15
10
2020
Statut:
ppublish
Résumé
The aim of this study was to analyze neuropathic pain (NeP) and its therapy in patients with Guillain-Barré syndrome (GBS) during a 6-month follow-up period. This longitudinal multicenter study included 69 newly diagnosed adult GBS patients. NeP diagnosis was based on the criteria of Finnerup and confirmed by the PainDETECT Questionnaire (PD-Q). Severity of GBS was assessed by GBS disability scale (GDS). Patients were assessed: on day 14 (D14), day 28 (D28), month 3 (M3), and month 6 (M6) from the disease onset. At D14, pain was present in 85.5% of patients, while 26.4% had NeP. At M6, 72.5% of patients had pain, 20.0% of them NeP. In acute GBS, pain intensity was higher in patients with NeP compared to those with non-NeP (p < 0.01). Pain intensity in patients with NeP did not change during time, but it decreased in patients with non-NeP at M6 (p < 0.05). Around 20% of GBS patients were on specific NeP medication throughout the observed period. One quarter of patients with NeP were not on specific NeP drug in the acute phase. Up to one third of patients with NeP were on NeP medication but still had significant NeP. Pooled PD-Q score was in correlation with pooled GDS score (rho = + 0.43, p < 0.01). NeP is a common and potentially severe symptom in GBS that may persist for months. It is important to recognize NeP, start specific treatment on time, in adequate doses, and for prolonged period of time.
Identifiants
pubmed: 33057880
doi: 10.1007/s11845-020-02395-0
pii: 10.1007/s11845-020-02395-0
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1137-1142Subventions
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : 175083
Informations de copyright
© 2020. Royal Academy of Medicine in Ireland.
Références
Sejvar JJ, Kohl KS, Gidudu J et al (2011) Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29:599–612
doi: 10.1016/j.vaccine.2010.06.003
Ruts L, Drenthen J, Longen JLM et al (2010) Pain in Guillain-Barre´ syndrome. A long-term follow-up study. Neurology 75:1439–1447
doi: 10.1212/WNL.0b013e3181f88345
Moulin DE, Hagen N, Feasby TE et al (1997) Pain in Guillain-Barré syndrome. Neurology. 48(2):328–331
doi: 10.1212/WNL.48.2.328
Bernsen RA, Jager AE, Schmitz PI, van der Meché FG (2001) Long-term sensory deficit after Guillain-Barré syndrome. J Neurol 248(6):483–486
doi: 10.1007/s004150170157
Forsberg A, Press R, Einarsson U et al (2004) Impairment in Guillain-Barré syndrome during the first 2 years after onset: a prospective study. J Neurol Sci 227:131–138
doi: 10.1016/j.jns.2004.09.021
Ruts L, van Koningsveld R, Jacobs BC, van Doorn PA (2007) Determination of pain and response to methylprednisolone in Guillain-Barré syndrome. J Neurol 254(10):1318–1322
doi: 10.1007/s00415-006-0515-2
Artemiadis AK, Panagiotis Z (2018) Neuropathic pain in acute and subacute neuropathies: a systematic review. Pain Physician 21:111–120
doi: 10.36076/ppj.2018.2.111
Martinez V, Fletcher D, Martin F et al (2010) Small fibre impairment predicts neuropathic pain in Guillain-Barré syndrome. Pain 151:53–60
doi: 10.1016/j.pain.2010.05.017
Dimachkie MM, Barohn RJ (2013) Guillain-Barré syndrome and variants. Neurol Clin 31(2):491–510
doi: 10.1016/j.ncl.2013.01.005
Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750–753
doi: 10.1016/S0140-6736(78)92644-2
Finnerup NB, Haroutounian S, Kamerman P et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain 157(8):1599–1606
doi: 10.1097/j.pain.0000000000000492
Attal N, Bouhassira D, Baron R (2018) Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol 17(5):456–466
doi: 10.1016/S1474-4422(18)30071-1
Freynhagen R, Baron R, Gockel U, Tolle TR (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22:1911–1920
doi: 10.1185/030079906X132488
Ruts L, van Doorn PA, Lombardi R et al (2012) Unmyelinated and myelinated skin nerve damage in Guillain–Barré syndrome: correlation with pain and recovery. Pain 153:399–409
doi: 10.1016/j.pain.2011.10.037
Pandey CK, Bose N, Garg G et al (2002) Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg 95(6):1719–1723
doi: 10.1097/00000539-200212000-00046
Pandey CK, Raza M, Tripathi M et al (2005) The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre´ syndrome patients in the intensive care unit. Anesth Analg 101:220–225
doi: 10.1213/01.ANE.0000152186.89020.36
Tripathi M, Kaushik S (2000) Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med 28(3):655–658
doi: 10.1097/00003246-200003000-00009
Koga M, Yuki N, Hirata K (2000) Pain in Miller Fisher syndrome. J Neurol 247(9):720–721
doi: 10.1007/s004150070122
Khatri A, Pearlstein L (1997) Pain in Guillain-Barré syndrome. Neurology 49(5):1474–141474. https://doi.org/10.1212/WNL.49.5.1474
doi: 10.1212/WNL.49.5.1474
pubmed: 9371954
Sanchez-Guerra M, Infante J, Pascual J, Berciano J (2002) Severe backache in Guillain-Barre´ syndrome. Muscle Nerve 25:468
doi: 10.1002/mus.1228
Kabore R, Magy L, Boukhris S et al (2004) Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome. Rev Neurol (Paris) 160(8–9):821–823
doi: 10.1016/S0035-3787(04)71037-1
Bernsen RA, Jacobs HM, de Jager AE, van der Meche FG (1997) Residual health status after Guillain-Barre´ syndrome. J Neurol Neurosurg Psychiatry 62:637–640
doi: 10.1136/jnnp.62.6.637
Bernsen RA, de Jager AE, Schmitz PI et al (1999) Residual physical outcome and daily living 3 to 6 years after Guillain-Barre´ syndrome. Neurology 53:409–410
doi: 10.1212/WNL.53.2.409
Bernsen RA, de Jager AE, Schmitz PI et al (2002) Long-term impact on work and private life after Guillain-Barre´ syndrome. J Neurol Sci 201:13–17
doi: 10.1016/S0022-510X(02)00158-2
Bernsen RA, de Jager AE, van der Meché FG et al (2005) How Guillain-Barre´ patients experience their functioning after one year. Acta Neurol Scand 112:51–56
doi: 10.1111/j.1600-0404.2005.00429.x
Mullings KR, Alleva JT, Hudgkins TH (2010) Rehabilitation of GuillainBarré syndrome. Dis Mon 56(5):288–292
doi: 10.1016/j.disamonth.2010.02.008
Rajabally YA, Uncini A (2012) Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 83(7):711–718
doi: 10.1136/jnnp-2011-301882
Martic V, Bozovic I, Berisavac I et al (2018) Three-year follow-up study in patients with Guillain-Barré syndrome. Can J Neurol Sci 45:269–274
doi: 10.1017/cjn.2018.12
Yao S, Chen H, Zhang Q et al (2018) Pain during the acute phase of Guillain–Barré syndrome. Medicine (Baltimore) 97(34):e11595. Published online 2018 Aug 24. https://doi.org/10.1097/MD.0000000000011595
doi: 10.1097/MD.0000000000011595